



Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference

March 2, 2021

BOSTON--(BUSINESS WIRE)--Mar. 2, 2021-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate in the virtual H.C. Wainwright Global Life Sciences Conference. The fireside chat will be made available for on-demand listening beginning Tuesday, March 9, 2021 at 7:00 a.m. EST.

The webcast of the fireside chat will be available on the "Media" section of the Company's website at www.verastem.com under "Events & Presentations".

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210302005061/en/): <https://www.businesswire.com/news/home/20210302005061/en/>

Verastem Oncology Contacts:

Investors:

Ajay Munshi

Vice President, Corporate Development

+1 781-469-1579

amunshi@verastem.com

Sherri Spear

Argot Partners

+1 212 600 1902

sherri@argotpartners.com

Media:

Lisa Buffington

Corporate Communications

+1 781-292-4205

lbuffington@verastem.com

Source: Verastem, Inc.